

# Marie Bleakley

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9987374/publications.pdf>

Version: 2024-02-01

18  
papers

1,939  
citations

840776

11  
h-index

888059

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

3222  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hematopoietic Cell Transplantation after CD19 Chimeric Antigen Receptor T Cell-Induced Acute Lymphoblastic Leukemia Remission Confers a Leukemia-Free Survival Advantage. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 21-29.	1.2	31
2	Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. <i>Blood</i> , 2022, 139, 1694-1706.	1.4	36
3	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 1174-1185.	1.6	36
4	Targeting an alternate Wilms's tumor antigen 1 peptide bypasses immunoproteasome dependency. <i>Science Translational Medicine</i> , 2022, 14, eabg8070.	12.4	12
5	Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2022, 36, 1563-1574.	7.2	2
6	Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry. <i>Journal of Immunological Methods</i> , 2021, 492, 112955.	1.4	1
7	Naive T-cell depletion in stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 4980-4980.	5.2	7
8	T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. <i>Nature Medicine</i> , 2019, 25, 1064-1072.	30.7	226
9	Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse. <i>Blood</i> , 2018, 131, 108-120.	1.4	73
10	Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. <i>Blood</i> , 2017, 129, 3322-3331.	1.4	861
11	Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. <i>Journal of Clinical Investigation</i> , 2015, 125, 2677-2689.	8.2	232
12	Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells. , 2014, 2, 36.		57
13	Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 705-716.	2.0	93
14	Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2012, 1, 103-111.	1.3	39
15	Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. <i>Immunology and Cell Biology</i> , 2011, 89, 396-407.	2.3	122
16	Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. <i>Blood</i> , 2010, 115, 4923-4933.	1.4	98
17	Human Minor Histocompatibility Antigen-Specific CD8+ T Cells Are Found Predominantly in the CD45RA+ CD62L+ Naïve T Cell Subset. <i>Blood</i> , 2005, 106, 578-578.	1.4	7
18	Human CD8+ Minor Histocompatibility Antigen Specific Cytotoxic T Lymphocyte Clones Can Be Generated by Primary In Vitro Stimulation of Naïve T Cells with Dendritic Cells from HLA Identical Siblings. <i>Blood</i> , 2004, 104, 2116-2116.	1.4	6